--- title: "BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 10-K: FY2025 Revenue: USD 41.71 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/279843564.md" datetime: "2026-03-19T20:19:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279843564.md) - [en](https://longbridge.com/en/news/279843564.md) - [zh-HK](https://longbridge.com/zh-HK/news/279843564.md) --- # BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 10-K: FY2025 Revenue: USD 41.71 M Revenue: As of FY2025, the actual value is USD 41.71 M. EPS: As of FY2025, the actual value is USD -1.04. EBIT: As of FY2025, the actual value is USD -10.9 M. Biofrontera Inc. operates as a single segment, with all revenues derived from the United States, primarily from Ameluz and RhodoLED Lamps . #### Segment Revenue Net product revenue for 2025 increased to $41,705 thousand from $37,303 thousand in 2024, representing an increase of $4,402 thousand or 11.8% . This growth was mainly driven by a $4,100 thousand increase in Ameluz sales volume and a $700 thousand increase due to a higher Ameluz unit price, partially offset by a $300 thousand decline in RhodoLED Lamps sales . Ameluz (including RhodoLED Lamps) accounted for approximately 100% of the company’s revenue . #### Operational Metrics - **Net Loss:** The company reported a net loss of - $10,536 thousand in 2025, which is an improvement from a net loss of - $17,759 thousand in 2024 . - **Loss from Operations:** The loss from operations improved to - $11,348 thousand in 2025 from - $17,210 thousand in 2024 . - **Total Operating Expenses:** Total operating expenses decreased to $53,053 thousand in 2025 from $54,531 thousand in 2024 . - **Cost of Revenues, Related Party:** This decreased by $7,700 thousand, or 43.4%, to $10,111 thousand in 2025 from $17,855 thousand in 2024, primarily due to a change in the commercial arrangement with the Biofrontera Group and $2,100 thousand of forgiven accrued purchase price, partially offset by $2,200 thousand in earnout payments . - **Cost of Revenues, Other:** This increased to $853 thousand in 2025 from $752 thousand in 2024 . - **Selling, General and Administrative (SG&A) Expenses:** These increased by $4,000 thousand, or 11.7%, to $37,751 thousand in 2025 from $33,793 thousand in 2024, mainly due to a $6,600 thousand rise in general and administrative expenses . This increase was partially offset by reductions in direct sales personnel expenses, sales support activities, a Xepi Prescription Drug User fee write-off, and intangible asset amortization . - **Selling, General and Administrative Expenses, Related Party:** These increased by $600 thousand to $619 thousand in 2025 from $42 thousand in 2024, primarily due to commercialization, regulatory, and manufacturing-related expenses . - **Research and Development (R&D) Expenses:** These increased by $1,600 thousand to $3,719 thousand in 2025 from $2,089 thousand in 2024, as the company assumed full responsibility for Ameluz clinical trial activities in the U.S. . - **Adjusted EBITDA (non-GAAP):** Adjusted EBITDA improved from - $15,258 thousand in 2024 to - $10,571 thousand in 2025, with the Adjusted EBITDA margin improving from -40.9% to -25.4% . #### Cash Flow - **Net Cash Used in Operating Activities:** Operating activities used - $13,361 thousand of cash in 2025, an increase from - $10,270 thousand in 2024 . - **Net Cash Provided by (Used in) Investing Activities:** Investing activities provided $2,998 thousand in 2025, compared to - $3 thousand used in 2024, primarily due to $3,000 thousand in proceeds from the sale of the Xepi product line . - **Net Cash Provided by Financing Activities:** Financing activities provided $10,850 thousand in 2025, down from $14,835 thousand in 2024, including $10,850 thousand in net proceeds from the issuance of Series C Preferred Stock . #### Unique Metrics - **Change in Fair Value of Warrant Liabilities:** The change in fair value resulted in a gain of $899 thousand in 2025, compared to a gain of $1,680 thousand in 2024, primarily due to a decrease in the underlying value of the company’s common stock . - **Gain on Sale of Asset Held for Sale:** The company recognized a gain of $700 thousand in 2025 from the sale of its Xepi product line . - **Earnout Payments:** Earnout payments to the Biofrontera Group totaled $2,200 thousand in 2025, recognized in cost of revenues . #### Outlook / Guidance Management believes there is substantial doubt about the company’s ability to continue as a going concern for at least twelve months from the report’s issuance date . The company plans to address this by expanding Ameluz commercialization, controlling expenses, and expecting an additional $1,000 thousand in milestone payments from the Xepi asset sale . Biofrontera Inc. also intends to secure additional capital through equity or debt financings if necessary, though there is no assurance of obtaining sufficient funding on acceptable terms . ### Related Stocks - [BFRIW.US](https://longbridge.com/en/quote/BFRIW.US.md) ## Related News & Research - [US strategic oil reserve hits lowest level since 2024 amid record draw](https://longbridge.com/en/news/286956962.md) - [FOCUS-As cocoa prices melt down, real chocolate is making a comeback](https://longbridge.com/en/news/287091302.md) - [22:13 ETGLOB Investors Have Opportunity to Lead Globant S.A. Securities Fraud Lawsuit](https://longbridge.com/en/news/286842370.md) - [Rich nations topped $100 bn climate finance goal again in 2023, 2024: OECD](https://longbridge.com/en/news/287193030.md) - [Always-on fraud checks cut Suncoast's losses by a third](https://longbridge.com/en/news/286815368.md)